Supplementary Figure S4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Samantha I. Liang; Zoe Quandt; Sara Wienke; Jing Wang; Sean Gordon; Reagan M. Barnett; Jude Masannat; Kyle Chang; Carin R. Espenschied; Katie Quinn; Kimberly C. Banks; Enjun Yang; John E. Connolly

doi:10.1158/2767-9764.29948087

August 20, 2025Open Access

Supplementary Figure S4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper

Ask AI

Bookmark

Share

Key Points

Tumor fraction changes significantly predict long-term clinical benefit from immune checkpoint inhibitors, emphasizing their relevance in treatment planning.
The analysis identified critical thresholds for tumor fraction change, providing specific metrics for assessing patient outcomes with this intervention.
Using a forest plot analysis, the study examined real-world data across various cancer types, highlighting the importance of ctDNA monitoring in clinical settings.
Findings support the potential for personalized therapy approaches in immuno-oncology, indicating further research is necessary to validate these observations.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Analysis shows tumor fraction changes predict clinical benefit in patients receiving immune checkpoint inhibitors, suggesting potential for improved therapy outcomes.

Abstract

Forest Plot analysis for percentage TF change threshold determination

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af55d8ad7bf08b1eadc77a https://doi.org/10.1158/2767-9764.29948087

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers